You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
Gilead Sciences to Acquire Arresto Biosciences for $225 Million
Department of Justice Declines to Intervene in Lawsuit against Gilead Sciences Regarding Ranexa(R)
Gilead Sciences to Present at the NASDAQ OMX 25th Investor Program
Gilead Sciences to Present at the 22nd Annual Piper Jaffray Healthcare Conference on Tuesday, November 30
Gilead Sciences Submits New Drug Application to U.S. FDA for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for HIV
Dr. Paul Berg to Retire from Gilead Sciences' Board of Directors
Gilead Sciences to Present at the 2010 CreditSuisse Healthcare Conference on Thursday, November 11
Viread(R) for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment
Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study
Gilead's Cayston(R) Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study
Gilead Sciences Announces Third Quarter 2010 Financial Results
Gilead Sciences to Release Third Quarter 2010 Financial Results on Tuesday, October 19, 2010
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Monday, September 20
Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Gilead Provides Update on $5 Billion Stock Repurchase Program
Gilead Sciences Announces Notification of ANDA Filing for Hepsera(R)
Gilead Closes Sale of $2.2 Billion of Convertible Senior Notes
Gilead Prices $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock
Gilead to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock
Gilead Sciences Announces Second Quarter 2010 Financial Results
Gilead Sciences Files Patent Infringement Lawsuit Against Lupin Limited
Gilead Sciences to Release Second Quarter 2010 Financial Results on Tuesday, July 20, 2010
Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million
Gilead's Head-to-Head Study of Cayston(R) Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-Inferiority
Gilead Sciences Announces Notification of ANDA Filing for Ranexa(R)
John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice President, Liver Disease Therapeutics
Gilead Sciences and ADAP Crisis Task Force Announce New Initiatives to Support AIDS Drug Assistance Programs (ADAPs)
Gilead Sciences to Present at the Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9
Gilead Sciences to Present at the Sanford C. Bernstein 26th Annual Strategic Decisions Conference on Thursday, June 3
Gilead Sciences to Present at the 2010 Citi Investment Research Global Health Care Conference on Wednesday, May 26
Gilead Announces $5 Billion Share Repurchase Program
Gilead Sciences to Present at the Banc of America Merrill Lynch 2010 Healthcare Conference on Thursday, May 13
Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278
Gilead Sciences Announces Record First Quarter 2010 Financial Results
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278
Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With Chronic Hepatitis C
Gilead Sciences to Release First Quarter 2010 Financial Results on Tuesday, April 20, 2010
Gilead Initiates Phase III Clinical Program Evaluating Single-Tablet, Once-Daily "Quad" Regimen for HIV
Gilead Sciences to Present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24
Gilead Sciences to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11
U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa
Gilead's Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study
Gilead Sciences to Present at the 12th Annual BIO CEO Investor Conference on Tuesday, February 9
Gilead Announces Share Repurchase Program
Per Wold-Olsen Joins Gilead Sciences' Board of Directors
Gilead Sciences Announces Notification of ANDA Filing for Viread®
Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results
Gilead Sciences to Release Fourth Quarter and Year End 2009 Financial Results on Tuesday, January 26, 2010
Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary Objective
2012 Interactive Annual Report